Participated in Zag Bio's $80M launch financing for thymus-targeted autoimmune therapies.
Zag Bio is a development stage biotechnology company focused on developing therapeutics to treat autoimmune diseases by training tissue-specific T regulatory cells to enable tolerance induction
Zag Bio is a development stage biotechnology company focused on developing therapeutics to treat autoimmune diseases by training tissue-specific T regulatory cells to enable tolerance induction.